Renauxe Pharma India Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 13-12-2024
- Paid Up Capital ₹ 3.23 M
as on 13-12-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.83 Cr
as on 13-12-2024
- Revenue -4.34%
(FY 2021)
- Profit 2.14%
(FY 2021)
- Ebitda -4.09%
(FY 2021)
- Net Worth 27.99%
(FY 2021)
- Total Assets -0.62%
(FY 2021)
About Renauxe Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.23 M.
The company currently has active open charges totaling ₹1.83 Cr.
Preeti Mathew and Stelinpullamkottu Mathai serve as directors at the Company.
- CIN/LLPIN
U24233KL2010PTC025811
- Company No.
025811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Renauxe Pharma India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Stelinpullamkottu Mathai  | Managing Director | 07-Apr-2010 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Preeti Mathew | Director | 07-Apr-2010 | Current |
Financial Performance of Renauxe Pharma India.
Renauxe Pharma India Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 4.34% decrease. The company also saw a slight improvement in profitability, with a 2.14% increase in profit. The company's net worth Soared by an impressive increase of 27.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renauxe Pharma India?
In 2021, Renauxe Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biocent Scientific India Private LimitedActive 8 years 1 monthPreeti Mathew and Stelinpullamkottu Mathai are mutual person
Westler Lifescience India Private LimitedActive 6 years 1 monthStelinpullamkottu Mathai is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Oct 2024 | ₹1.00 M | Open |
Others Creation Date: 18 Mar 2024 | ₹1.59 Cr | Open |
Hdfc Bank Limited Creation Date: 14 Jan 2021 | ₹1.41 M | Open |
How Many Employees Work at Renauxe Pharma India?
Renauxe Pharma India has a workforce of 45 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renauxe Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renauxe Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
